CDK4 and mantle cell lymphoma: Importantly, among the downstream targets of PI3K/AKT are the catalytic partners of cyclin D1, CDK4 and CDK6, the inhibition of which can modify MCL cell cycle and reprogram the cells toward a re-sensitization to p110δ inhibition [57].